GlaxoSmithKline hopes to supply Australia’s subsequent COVID remedy


GSK introduced final yr that it plans to shut its Melbourne manufacturing website in Boronia by the tip of 2022 after 50 years. The corporate’s analysis on COVID remedy has been abroad, with a low variety of instances in Australia which means it’s tough to make trials for remedies right here.

Australia is at the moment centered on the launch of coronavirus vaccines, however the native biotech sector has lengthy stated there must be extra remedy choices for sufferers presenting with the virus – notably when borders reopen.

ASX-listed corporations have rapidly turned to antivirus and preventative remedies over the previous yr, together with Melbourne’s Starpharma which efficiently introduced a nasal spray to market within the UK final month.

Not all tasks have labored, with native vaccine producer CSL and its Japanese rival Takeda lately repairing a yr of labor on a remedy concept utilizing the plasma of recovered sufferers.

The primary remedy accredited in Australia by the TGA was Gilead’s remdesivir product, which has been accredited to be used in sufferers who’ve been hospitalized with the virus.

The GSK monoclonal antibody product is as a substitute supposed to be used in sufferers who usually are not but in hospital however are prone to turning into in poor health.

In a press release on the provisional dedication, the TGA defined that monoclonal antibodies reminiscent of these utilized by GSK have already been implicated in numerous different situations.

GSK’s monoclonal antibody product is meant to be used in sufferers who usually are not but in hospital however are prone to turning into in poor health.Credit score:Petru Braig

“Monoclonal antibodies may also assist to‘ reject ’an immune response when the physique reacts excessively, which may occur with some COVID-19 sufferers. [they] may also help deal with individuals who have already got COVID-19, ”the regulator stated in a press release. GSK will now proceed to supply knowledge to the TGA.

The provisional dedication of the TGA is step one within the approval course of. The regulator says that “doesn’t imply that an utility is or will probably be made, or that the remedy will probably be provisionally accredited to be included within the Australian Register of Therapeutic Property”, nonetheless.


The choice lets GSK begin offering the regulator with knowledge dossiers on the product that would result in accelerated approvals.

“The following steps will probably be accessible knowledge [on the treatment], and we’re working as quickly as doable to get the information to the TGA for evaluation, ”stated Dr. Evans.

Enterprise briefing

Begin the day with nice tales, unique protection and knowledgeable opinions from our main enterprise journalists forwarded to your inbox. Join right here.

Essentially the most seen in enterprise



Please enter your comment!
Please enter your name here